Effect of mobility impairment on indirect and intangible costs#.

<p>EQ-5D =  EuroQol 5 Dimension, MSWS-12 =  Multiple Sclerosis Walking Scale, Q = question number, SD = standard deviation,</p><p>WTP =  willingness-to-pay.</p>*<p>No mobility impairment was used as referent,</p>†<p>P<0.001.</p>#<p>Sample sizes for each scale varied due to survey completeness.</p

Effect of mobility impairment categorized by Patient Determined Disease Steps and the NARCOMS Mobility Performance Scale on indirect and intangible costs#.

<p>EQ-5D =  EuroQol 5 Dimension, MS = Multiple Sclerosis, PDDS =  Patient Determined Disease Steps (scores of 0–2 representing “no walking disability”, 3–5 as “mild-to-moderate” and 6–8 as “severe-to-total”), PS =  Performance Scale, Q = question number, SD = standard deviation, WTP =  willingness-to-pay.</p>*<p>No mobility impairment was used as referent,</p>†<p>P<0.001.</p>#<p>Sample sizes for each scale varied due to survey completeness.</p

Indirect Costs and EQ-5D Health Utility Scores by NARCOMS Performance Scale Categories.

<p>Mobility Performance Scale =  “In the past 4 weeks, compare your current condition to your mobility before you developed MS”.</p

NARCOMS Participant Demographics (n = 3,728).

<p>NARCOMS = North American Research Committee on Multiple Sclerosis.</p

Additional file 1: of External validation of prognostic rules for early post-pulmonary embolism mortality: assessment of a claims-based and three clinical-based approaches

Description of the IMPACT, PESI, sPESI and Hestia Prediction Rules. Table S1. Characteristics of Pulmonary Embolism Patients in the 30-Day Mortality Cohort. Table S2. Description of Patients Whom Died In-Hospital and Had Discordant Risk Categorization. Table S3. Description of Patients Whom Died After Discharge and Within 30-days of Presentation and Had Discordant Risk Categorization. (DOCX 35 kb